Ключевые слова
Как цитировать
Аннотация
Хронический миелоидный лейкоз (ХМЛ) является крайне редким заболеванием в педиатрической практике, насчитывая до 2–3 % всех случаев лейкемии у детей до 15 лет и до 9 % у пациентов подросткового возраста (15–19 лет). Диагностика и лечение ХМЛ у детей и подростков имеют ряд отличий по сравнению со взрослыми, что, наряду с редкостью патологии, актуализирует представляемую проблему. ХМЛ у детей может иметь более агрессивное течение, обусловливая тяжесть клинической симптоматики в дебюте заболевания.
В статье представлено описание клинических случаев ХМЛ у пациентов детского возраста с акцентом на особенности дебюта заболевания, спектр ассоциированных осложнений, подходы к специфической и сопроводительной терапии.
Библиографические ссылки
Suttorp M., Millot F., Sembill S., et al. Definition, epidemiology, pathophysiology, and essential criteria for diagnosis of pediatric chronic myeloid leukemia. Cancers (Basel). 2021; 13(4): 798.-DOI: https://doi.org/10.3390/cancers13040798.
Athale U., Hijiya N., Patterson B.C., et al. Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. Pediatr Blood Cancer. 2019; 66(9): e27827.-DOI: https://doi.org/10.1002/pbc.27827.
Giona F., Bianchi S. Update in childhood chronic myeloid leukemia. Hemato. 2022; 3(4): 718-730.-DOI: https://doi.org/10.3390/hemato3040048.
Moschovi M., Kelaidi C. Chronic myeloid leukemia in children and adolescents: The achilles heel of oncogenesis and tyrosine kinase inhibitors. Int J Mol Sci. 2021; 22(15): 7806.-DOI: https://doi.org/10.3390/ijms22157806.
Бойченко Э.Г. Хронический миелолейкоз у детей: редкая и уникальная болезнь. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2022; 21(1): 156-172.-DOI: https://doi.org/10.24287/1726-1708-2022-21-1-156-172. [Boychenko E.G. Two case reports of bilateral adrenal myelolipomas. Pediatric Hematology/Oncology and Immunopathology. 2022; 21(1): 156-172.-DOI: https://doi.org/10.24287/1726-1708-2022-21-1-156-172 (In Rus)].
Patel A.A., Patel K.M., Jain A. Chronic myeloid leukemia in childhood: Review Article. GCSMC J Med Sci. 2013; 2(2): 5-8.-URL: https://gcsmc.org/assets/pdf/journal/journal-1222/review-article/chronic-myeloid-leukemia-in-childhood201810051723075952430.pdf.
Meral Günes A., Millot F., Kalwak K., et al. Features and outcome of chronic myeloid leukemia at very young age: Data from the International Pediatric Chronic Myeloid Leukemia Registry. Pediatr Blood Cancer. 2021; 68(1): e28706.-DOI: https://doi.org/10.1002/pbc.28706.
Hijiya N., Schultz K.R., Metzler M., et al. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016; 127(4): 392-399.-DOI: https://doi.org/10.1182/blood-2015-06-648667.
Hochhaus A., Baccarani M., Silver R.T., et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4): 966-984.-DOI: https://doi.org/10.1038/s41375-020-0776-2.
Kreipe H.H., Schlegelberger B. Cytogenetics and genomics in CML and other myeloproliferative neoplasms. Best Pract Res Clin Haematol. 2024; 37(2): 101552.-DOI: https://doi.org/10.1016/j.beha.2024.101552.
Athale U., Hijiya N., Patterson B.C., et al. Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. Pediatr Blood Cancer. 2019; 66(9): e27827.-DOI: https://doi.org/10.1002/pbc.27827.
Carofiglio F., Lopalco A., Lopedota A., et al. Bcr-Abl tyrosine kinase inhibitors in the treatment of pediatric CML. Int J Mol Sci. 2020; 21(12): 4469.-DOI: https://doi.org/10.3390/ijms21124469.
Behrens Y.L., Gaschler L.., Nienhold R, et al. Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia. Haematologica. 2024; 109(3): 942-947.-DOI: https://doi.org/10.3324/haematol.2023.283800.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Chronic Myeloid Leukemia. Version 3.2025. Plymouth Meeting (PA): National Comprehensive Cancer Network. 2025.-URL: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1427.
Baccarani M., Deininger M.W., Rosti G., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6): 872-884.-DOI: https://doi.org/10.1182/blood-2013-05-501569.
Kantarjian H.M., Tefferi A. Classification of accelerated phase chronic myeloid leukemia in the era of the BCR: ABL1 tyrosine kinase inhibitors: A work in progress. Am J Hematol. 2023; 98(9): 1350-1353.-DOI: https://doi.org/10.1002/ajh.27007.
Wang W., Cortes J.E., Tang G., et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016; 127(22): 2742-2750.-DOI: https://doi.org/10.1182/blood-2016-01-690230.
Jin M., Xuan C., Gao J., et al. Chronic myeloid leukemia extramedullary blast crisis presenting as central nervous system leukemia: A case report. Medicine (Baltimore). 2018; 97(45): e13131.-DOI: https://doi.org/10.1097/md.0000000000013131.
Yahyaoui A., Douichi I., Ouahabi N., et al. Pediatric chronic myeloid leukemia: a case report of a disease with a unique biology. PAMJ Clinical Medicine. 2024; 14: 41.-DOI: https://doi.org/10.11604/pamj-cm.2024.14.41.42993.
AlGahtani F.H., Alshaman L., ElGohary G., et al. Bleeding diathesis as the initial presentation of chronic myeloid leukemia: A case series. Cureus. 2023; 15(4): e37201.-DOI: https://doi.org/10.7759/cureus.37201.
Ahmed A., Saeed S., Soliman D.S., et al. Hematoma or bleeding as initial presentation of chronic myeloid leukemia (CML): Review. Blood. 2022; 140(Supplement 1): 12231–12232.-DOI: https://doi.org/10.1182/blood-2022-160132.
Минздрав России. Клинические рекомендации: Хронический миелоидный лейкоз. 2024.-URL: https://cr.minzdrav.gov.ru/view-cr/889_1. [Ministry of Health of the Russian Federation. Clinical recommendations: Chronic myeloid leukemia. 2024.-URL: https://cr.minzdrav.gov.ru/view-cr/889_1 (In Rus)].
Osman A.E.G., Deininger M.W. Chronic myeloid leukemia: Modern therapies, current challenges and future directions. Blood Rev. 2021; 49: 100825.-DOI: https://doi.org/10.1016/j.blre.2021.100825.
Sun J., Hu R., Han M., et al. Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Biol Sci. 2024; 20(1): 175-181.-DOI: https://doi.org/10.7150/ijbs.86305.
Chaudhury S., Sparapani R., Hu Z.H., et al. Outcomes of allogeneic hematopoietic cell transplantation in children and young adults with chronic myeloid leukemia: A CIBMTR cohort analysis. Biol Blood Marrow Transplant. 2016; 22(6): 1056-1064.-DOI: https://doi.org/10.1016/j.bbmt.2016.02.015.
Ayatollahi H., Keramati M.R., Shirdel A., et al. BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran. Caspian J Intern Med. 2018; 9(1): 65-70.-DOI: https://doi.org/10.22088/cjim.9.1.65.
Королев Г.А., Пименова Е.С., Морозов Д.А. Применение опросника PedsQL 4.0 в оценке качества жизни детей с нарушениями дефекации, оперированных по поводу врожденных пороков развития. Российский вестник детской хирургии, анестезиологии и реаниматологии. 2022; 12(2): 177–86.-DOI: https://doi.org/10.17816/psaic1010. [Korolev G.A., Pimenova E.S., Morozov D.A. Application of the PedsQL 4.0 questionnaire in assessing the quality of life of children with defecation disorders after surgical treatment of congenital malformations. Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care. 2022; 12(2): 177–86.-DOI: https://doi.org/10.17816/psaic1010 (In Rus)].
Varni J.W., Burwinkle T.M., Seid M., Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr. 2003; 3(6): 329-341.-DOI: https://doi.org/10.1367/1539-4409(2003)003 % 3C0329:tpaapp % 3E2.0.co;2.
Arana-Trejo R.M., Ruíz Sánchez E., Ignacio-Ibarra G., et al. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML). Clin Lab Haematol. 2002; 24(3): 145-150.-DOI: https://doi.org/10.1046/j.1365-2257.2002.00413.x.
van Rhee F., Hochhaus A., Lin F., et al. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood. 1996; 87(12): 5213-5217.-DOI: https://doi.org/10.1182/blood.V87.12.5213.bloodjournal87125213.
Hijiya N., Suttorp M. How I treat chronic myeloid leukemia in children and adolescents. Blood. 2019; 133(22): 2374-2384.-DOI: https://doi.org/10.1182/blood.2018882233.
Deshpande P.A., Padmawar G.B., Ekbote V.S. A novel in-frame 231bp deletion mutation in ABL1 kinase activation loop. Indian J Med Paediatr Oncol. 2019; 40: 141-3.-DOI: https://doi.org/10.4103/ijmpo.ijmpo_221_17.
Patkar N., Ghodke K., Joshi S., et al. Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance. Leuk Lymphoma. 2016; 57(11): 2653-2660.-DOI: https://doi.org/10.3109/10428194.2016.1157868.
Ионова Т.И., Никитин Т.П., Ломаиа Е.Г., et al. Показатели качества жизни, профиль симптомов и клинический эффект терапии второй линии дазатинибом у больных хроническим миелолейкозом при резистентности или непереносимости предшествующей терапии иматинибом: результаты 2-летнего мониторинга. Онкогематология. 2015; 10(3): 18-27.-DOI: https://doi.org/10.17650/1818-8346-2015-10-3-18-27. [Ionova T.I., Nikitina T.P., Lomaia E.G., et al. Quality of life, symptom profile and clinical efficacy of second-line treatment with dasatinib in patients with imatinib-resistant or -intolerant chronic myeloid leukemia: results of 2-year follow-up. Oncohematology. 2015; 10(3): 18-27.-DOI: https://doi.org/10.17650/1818-8346-2015-10-3-18-27 (In Rus)].
Schoenbeck K.L., Flynn K.E. Health-related quality of life of patients with chronic myeloid leukemia as measured by patient-reported outcomes: Current state and future directions. Curr Hematol Malig Rep. 2021; 16(6): 491-499.-DOI: https://doi.org/10.1007/s11899-021-00656-y.
Flynn K.E., Atallah E. Quality of life and long-term therapy in patients with chronic myeloid leukemia. Curr Hematol Malig Rep. 2016; 11(2): 80-85.-DOI: https://doi.org/10.1007/s11899-016-0306-5.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2026